Abstract:SESSION TITLE: Asthma III SESSION TYPE: Original Investigation Poster PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM PURPOSE: Asthmatic inflammation is dominated either by eosinophil or neutrophil accumulation in airways. Resolution of these inflammatory cells is the key to disease alleviation. It is well accepted that eosinophilic airway inflammation is responsive to corticosteroid treatment, while neutrophilic inflammation contributes to most of the corticosteroid-insensitive severe asthma and increases the burden of global health care. Here, we explored a new strategy of effective treatment against corticosteroid-insensitive neutrophilic asthma by small molecule inhibitors against anti-apoptotic protein Bcl-2. METHODS: Expression of Bcl-2 on inflammatory cells and inflamed tissues were detected. Resolution of airway inflammation in allergen-challenged Bcl-2 transgenic mice was analyzed. Mouse eosinophils and neutrophils from bronchoalveolar lavage (BAL) fluid in response to ABT-737 was detected by flow cytometry. Eosinophilic and neutrophilic airway inflammation model were treated with ABT-737 or ABT-199, the apoptosis of inflammatory cells and cytokines level were analyzed and airway hyperresponsiveness to aerosolized methacholine was measured. RESULTS: Significantly higher viability and prolonged lifespan of eosinophils and neutrophils were observed in BAL fluid from allergen-induced airway inflammation mouse model showed. This was probably due to elevated expression levels of Bcl-2 protein in these inflammatory cells. It was striking that inflammatory response induced by allergen dramatically aggravated and persisted in vav-Bcl-2 transgenic mice, where nucleated hematopoietic cells were resistant to apoptosis. Based on these above observations, Bcl-2 inhibitors, ABT-737 or ABT-199, were shown to play efficient roles in alleviation of either eosinophilic or neutrophilic allergen-induced airway inflammation. CONCLUSIONS: ABT-737 or ABT-199 may be promising drugs for the treatment against airway inflammation, especially corticosteroid-insensitive neutrophilic airway inflammation. CLINICAL IMPLICATIONS: It is well-accepted that eosinophilic airway inflammation is responsive to corticosteroid treatment, while neutrophilic inflammation contributes to most of the corticosteroid-insensitive severe asthma. We have provided a new strategy to inhibit allergic airway inflammation, especially the neutrophil-dominated and corticosteroid insensitive airway inflammation, by promoting the death of inflammatory cell with the antagonist of anti-apoptotic proteins Bcl-2 termed ABT-737 or ABT-199. DISCLOSURE: The following authors have nothing to disclose: Bao-ping Tian, Li-xia Xia, Zhengqiang Bao, Wen Li, Zhihua Chen, Songmin Ying, Huahao Shen No Product/Research Disclosure Information

Natural killer cell–mediated inflammation resolution is disabled in severe asthma

Involvement of Human Natural Killer Cells in Asthma Pathogenesis: Natural Killer 2 Cells in Type 2 Cytokine Predominance

Bcl-2 Inhibitors Reduce Steroid-Insensitive Airway Inflammation.

STAT3 and IL-6 Contribute to Corticosteroid Resistance in an OVA and Ozone-induced Asthma Model with Neutrophil Infiltration

Induction of Granulocyte Apoptosis by Bcl-2 Inhibitors Reduces Steroid-Insensitive Airway Inflammation

Bcl-2 Antagonist ABT-737 Attenuates Corticosteroid-Insensitive Neutrophilic Airway Inflammation

Bruton's tyrosine kinase inhibition suppresses neutrophilic inflammation and restores histone deacetylase 2 expression in myeloid and structural cells in a mixed granulocytic mouse model of asthma

Reasearch Progress on the Role of Neutrophils in Asthma

Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies

Pathogenesis of steroid-resistant airway hyperresponsiveness: interaction between IFN-gamma and TLR4/MyD88 pathways

Deficiency and dysfunctional roles of natural killer T cells in patients with ARDS

NF-kappaB Signaling in Chronic Inflammatory Airway Disease

TH17 cells and corticosteroid insensitivity in severe asthma

Targeting In Vivo Metabolic Vulnerabilities of Th2 and Th17 Cells Reduces Airway Inflammation

Targeted deletion of NFAT-Interacting-Protein-(NIP) 45 resolves experimental asthma by inhibiting Innate Lymphoid Cells group 2 (ILC2)

Pulmonary Administration of TLR2/6 Agonist after Allergic Sensitization Inhibits Airway Hyper-Responsiveness and Recruits Natural Killer Cells in Lung Parenchyma

Natural Killer Cells as a Further Insight into the Course of Chronic Obstructive Pulmonary Disease

[New Therapeutic Targets and Drugs for the Severe Asthma]

Neutrophil extracellular trap production and CCL4L2 expression influence corticosteroid response in asthma

Blockade of NLRP3/Caspase-1/IL-1β Regulated Th17/Treg Immune Imbalance and Attenuated the Neutrophilic Airway Inflammation in an Ovalbumin-Induced Murine Model of Asthma

Characteristics of airway inflammation in bronchial asthma